KCNB1 and metastatic prostate carcinoma: In addition, preclinical studies suggest a potential therapeutic role for Kv2.1 inhibition in various cancers, including metastatic prostate cancer, where it reduces cell migration (via ScTx1 and siRNA) [27], as well as cervical carcinomas [23], where it modulates cell proliferation and cycle progression (via hanatoxin-1).